Vanda Pharmaceutical, VNDA $22 premkt
Thursday, December 7, 2006 at 07:34AM December 1st in DJIM alerts at $15
Vanda Pharma announces it confirms Iloperidone efficacy with positive Phase III clinical trial results in Schizophrenia (VNDA) 15.50 :Co announced positive top-line results from the co's Phase III clinical trial evaluating iloperidone, an atypical antipsychotic, in patients with schizophrenia. Iloperidone demonstrated statistically significant improvement compared to placebo on the Positive and Negative Symptom Scale, the trial's primary endpoint. Additionally, iloperidone achieved significant efficacy on the positive and negative symptom subscales of PANSS. The safety profile was consistent with what has been observed in previous iloperidone Phase III trials. "We are extremely pleased to have achieved this outcome with iloperidone. The success of this trial moves us one step closer to our NDA filing, expected in late 2007, and one step closer to making iloperidone available to patients and providers dealing with schizophrenia."